JPRN-jRCT2031220732招募中2 期
iraparib vs. Niraparib in combination with Bevacizumab in patients with platinum-taxane based chemotherapy for post-operative ctDNA positive advanced ovarian cancer
Chiyoda Tatsuyuki0 个研究点目标入组 70 人开始时间: 2023年3月25日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- Female
入选标准
- •1. Participated in Genetic Alterations and clinical record in surgically debulked OVarian cancer patients by Liquid biopsy And whole eXome analYsis: GALAXY-OV trial with written consent.
- •2. Histopathologically diagnosed with primary ovarian cancer (including ovarian cancer, fallopian tube cancer, and peritoneal cancer).
- •3. 2014 FIGO classification stage III-IV
- •4. Interval debulking surgery (IDS) has been performed for primary and metastatic lesions.
- •5. Ovarian cancer tumor tissue or cell block was collected before neoadjuvant chemotherapy.
- •6. No more than 4 cycles of neoadjuvant chemotherapy.
- •7. Aged 18 years or older at the time of informed consent.
- •8. Oral intake is possible.
- •9. ctDNA positive in the SignateraTM analysis using postoperative blood specimens.
- •10. ECOG performance status (PS) of 0 or 1 at the time of informed consent for this study.
- •11. At the time of informed consent and screening test for this study, there is no severe damage to major organs (bone marrow, heart, lung, liver, kidney, etc.) and the following criteria are met. (Use the test results before the administration of postoperative chemotherapy immediately before registration. If there are no applicable laboratory test values, measure immediately before registration.)
- •- Neutrophil count >= 1,500/microliter
- •- platelet count >= 100,000/microliter
- •- hemoglobin >= 8.0 g/dL
- •- serum creatinine <= 1.5 * upper limit of normal (ULN)
- •- total bilirubin <= 1.5 * ULN
- •- ALT and AST <= 2.5 * ULN, <= 5 * ULN if liver metastases
- •12. Urine protein less than 2+ on urinalysis. If the urinalysis is 2+ or greater, the urinary protein/creatinine ratio is less than 1.
- •13. Normal blood pressure or appropriately treated and controlled hypertension (systolic BP 140 mmHg or less and/or diastolic BP 90 mmHg or less)
- •14.Written informed consent to participate in the study was obtained voluntarily after a full explanation of the study prior to enrollment in this study.
排除标准
- •1.Patients with sarcoma or non-epithelial ovarian cancer.
- •2.Have a history of malignant tumors other than ovarian cancer.
- •Patients with a recurrence-free interval of 5 years or longer, or basal or squamous cell carcinoma of the skin, superficial bladder cancer, cervical cancer, carcinoma in situ (carcinoma in situ) judged to have been cured by topical treatment or patients with lesions equivalent to intramucosal carcinoma can be enrolled.
- •3. HBs antigen positive, HBc antibody positive, or HCV antibody positive.
- •4. HIV antibody positive (registration is possible even if HIV antibody has not been tested).
- •5.History of interstitial lung disease (interstitial pneumonia, pulmonary fibrosis, etc.) requiring treatment, or extensive findings of these on CT.
- •6. Poorly controlled comorbidities or active infections.
- •7. Receiving continuous systemic administration (oral or intravenous) of corticosteroids (prednisolone equivalent of at least 10 mg/day for at least 2 weeks).
- •8.Previous treatment with Poly(ADP-ribose) polymerase (PARP) inhibitors.
- •9.The patient is judged to have difficulty enrolling in this clinical trial due to a clinically problematic psychiatric disorder.
- •10.History of hemoptysis.
- •11.History of hypertensive crisis (CTCAE Grade 4) or hypertensive encephalopathy.
- •12.History of cerebrovascular disease, transient ischemic attack, subarachnoid hemorrhage or posterior reversible encephalopathy syndrome.
- •13. Has a history or signs of bleeding disorders.
- •14.Bleeding diathesis or signs of severe hematological disorder (no blood clotting).
- •15. History or clinical suspicion of brain metastasis or spinal cord compression. If brain metastasis is suspected, brain CT/MRI (within 4 weeks before enrollment) is mandatory. Spinal cord MRI (within 4 weeks prior to enrollment) is mandatory if spinal cord compression is suspected.
- •16. History of central nervous system disease or signs on neurological examination, except when adequately managed with standard therapy.
- •17. Patient with Intractable wound, active ulcer or fracture. Patients treated with open granulation tissue therapy for secondary healing and no signs of superficial wound dehiscence or infection are eligible but require wound evaluation every 3 weeks.
- •18. Concomitant clinically significant intestinal obstruction.
- •19. Physical examination or laboratory findings that are contraindications to the use of niraparib and bevacizumab or that are reasonably suspicious of disease or morbidity that increases the risk of treatment-related complications.
- •20. Pregnant or breastfeeding women.
- •21. Participation in other clinical trials is not permitted. (except for clinical trials, etc. that do not involve therapeutic intervention)
- •22. The attending physician determines that the patient is not suitable for enrollment in this clinical trial.
研究者
相似试验
招募中
3 期
Evaluation of Niraparib alone compared to the combination of Niraparib and Bevacizumab in patients receiving chemotherapy for newly diagnosed advanced ovarian cancer2024-516066-11-00AGO Research GmbH970
进行中（未招募）
1 期
iraparib versus niraparib-bevacizumab combination in Women with platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer.platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancerMedDRA version: 20.0Level: PTClassification code 10016180Term: Fallopian tube cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10066697Term: Ovarian cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-004269-26-SEordic Society of Gynaecological Oncology - Clinical Trial Unit (NSGO-CTU)94
进行中（未招募）
1 期
iraparib alone or Niraparib and bevacizumab combination in Women with ovarian cancer.Women with relapsed platinum-sensitive epithelial ovarian cancerMedDRA version: 20.0Level: PTClassification code 10061328Term: Ovarian epithelial cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10061344Term: Peritoneal neoplasmSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10016180Term: Fallopian tube cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-004269-26-DKordic Society of Gynaecological Oncology - Clinical Trial Unit110
进行中（未招募）
1 期
iraparib and niraparib-bevacizumab combination against bevacizumab alone in Women with Homologous Recombination Deficient (HRD) platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer.Homologous Recombination Deficient (HRD) platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancerEUCTR2014-004269-26-NOordic Society of Gynaecological Oncology (NSGO)132
进行中（未招募）
1 期
iraparib and niraparib-bevacizumab combination against bevacizumab alone in Women with Homologous Recombination Deficient (HRD) platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer.Homologous Recombination Deficient (HRD) platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancerEUCTR2014-004269-26-FIordic Society of Gynaecological Oncology (NSGO)132